Conceivably, it is enough to see the dose-finding stage of CHM-2101 through to the all-important initiation of the Phase 2 part of the trial. It could keep the wolves at bay for a bit longer by splashing a bit of green on that white flag of the fiscally desperate who dare to be involved in the world of immuno-oncology.
Ann: Chimeric receives $2.5 M advance on FY25 R&D tax incentive, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $69.39K | 17.34M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 40 | 26298938 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 9308291 | 10 |
View Market Depth
| Last trade - 11.21am 18/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |